13.29
Precedente Chiudi:
$13.00
Aprire:
$12.935
Volume 24 ore:
4.53M
Relative Volume:
3.45
Capitalizzazione di mercato:
$495.88M
Reddito:
$15.84M
Utile/perdita netta:
$-308.48M
Rapporto P/E:
-2.0509
EPS:
-6.48
Flusso di cassa netto:
$-153.08M
1 W Prestazione:
+44.93%
1M Prestazione:
-2.99%
6M Prestazione:
+101.36%
1 anno Prestazione:
+184.58%
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
QURE
Uniqure N V
|
13.29 | 495.88M | 15.84M | -308.48M | -153.08M | -6.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2024-10-10 | Ripresa | Raymond James | Outperform |
2024-02-29 | Downgrade | Goldman | Buy → Neutral |
2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
2021-06-15 | Iniziato | BTIG Research | Buy |
2021-05-21 | Iniziato | UBS | Neutral |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-11-24 | Iniziato | H.C. Wainwright | Buy |
2020-11-11 | Iniziato | Berenberg | Buy |
2020-11-09 | Iniziato | Jefferies | Buy |
2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
2020-08-25 | Iniziato | Raymond James | Strong Buy |
2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2019-12-03 | Iniziato | Cowen | Outperform |
2019-12-03 | Iniziato | Goldman | Buy |
2019-11-05 | Iniziato | Credit Suisse | Outperform |
2019-10-11 | Iniziato | Stifel | Buy |
2019-09-25 | Iniziato | Bernstein | Outperform |
2019-09-12 | Iniziato | Mizuho | Buy |
2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
2019-04-12 | Iniziato | Piper Jaffray | Overweight |
2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance
uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha
uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN
FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com South Africa
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga
uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus
uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus
uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com South Africa
uniQure shares soar on FDA breakthrough therapy designation - Investing.com
FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com
uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | QURE Stock News - GuruFocus
UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus
Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView
uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq
uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results - Stock Titan
uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World
Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com
uniQure CEO secures amended employment agreement By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Buys 58,246 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure CEO secures amended employment agreement - Investing.com
uniQure Amends CEO Employment Agreement - TipRanks
Alliancebernstein L.P. Has $3.60 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
NEVADA KING ANNOUNCES INCREASE OF PHASE III PROGRAM TO 30,000M, REFINES REGIONAL TARGETS AT ATLANTA - The Globe and Mail
Institutional owners may ignore uniQure N.V.'s (NASDAQ:QURE) recent US$190m market cap decline as longer-term profits stay in the green - simplywall.st
(QURE) Long Term Investment Analysis - news.stocktradersdaily.com
uniQure (NASDAQ:QURE) Now Covered by Analysts at Chardan Capital - The AM Reporter
Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com
(QURE) Trading Report - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World
FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World
uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia
uniQure Reports 2024 Financial Results and Progress - TipRanks
uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India
uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India
uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa
uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):